MME and hydrops fetalis: The PROVE-HF trial demonstrated that Sacubitril/Valsartan, a combination of an angiotensin receptor blocker (ARB) and a neprilysin inhibitor (NEP inhibitor), improved NTproBNP levels and LV volumes at 12 months in patients with HFrEF, providing a reverse cardiac remodelling effect [33].